학술논문
Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature.
Document Type
Article
Author
Lecumberri, Ramón; Krsnik, Isabel; Askari, Elham; Sirvent, Maialen; González-Pérez, Marta S.; Escalante, Fernando; Pradillo, Virginia; Tamariz, Luis E.; Cánovas, Verónica; Alegre, Adrián; Gironella, Mercedes; González-García, María E.; Infante, María S.; Lakhwani, Sunil; Martínez-Bilbao, Cristina; Dourdil, Victoria; Ramírez-Payer, Ángel; Sarrá, José; Cibeira, M. Teresa
Source
Subject
*AMYLOIDOSIS
*LITERATURE reviews
*CARDIAC amyloidosis
*PROGRESSION-free survival
*RETROSPECTIVE studies
*DARATUMUMAB
*
*
*
*
*
Language
ISSN
1350-6129
Abstract
Management of patients with relapsed or refractory (R/R) AL amyloidosis is complex. Some initial reports have shown positive results with daratumumab in heavily pre-treated AL amyloidosis patients. In this retrospective multicentric study, 38 patients (mean age 64 ± 9 years) with R/R AL amyloidosis treated with daratumumab were included. Cardiac and renal involvement was present in 76 and 74% of patients, and 42% had ≥3 organs involved. Median number of previous lines of therapy was 2 (range 1–8). Overall hematological response was 72%, including 28% complete responses. The median time to first hematological response was 2 weeks. A high-quality response (≥very good partial response) was obtained in 65% of patients who had never achieved such depth of response previously. Hematological responses were more frequent among patients receiving daratumumab as second-line therapy compared to subsequent therapies (92 vs. 61%). Cardiac and renal organ response rates were 37 and 59%. At 12 months, overall and progression-free survival were 59% (95%CI: 0.36–0.77) and 52% (95%CI: 0.29–0.70), respectively. Daratumumab is a safe and effective drug in the treatment of R/R AL amyloidosis and should be considered early in the course of the disease. [ABSTRACT FROM AUTHOR]